Efficacy and Safety of Roflumilast in Patients with Asthma (BY217/M2-012)

Study identifier:BY217/M2-012

ClinicalTrials.gov identifier:NCT00073177

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A 24 Week, Double-Blind, Randomized, Placebo-Controlled Clinical Trial to evaluate the Efficacy and Safety of Oral Roflumilast (250 mcg or 500 mcg) Daily in Patients with Asthma

Medical condition

asthma

Phase

Phase 3

Healthy volunteers

No

Study drug

Roflumilast

Sex

All

Actual Enrollment

819

Study type

Interventional

Age

18 Years - 70 Years

Date

Study Start Date: 01 Nov 2003
Primary Completion Date: -
Study Completion Date: -

Study design

Allocation: Randomized
Endpoint Classification: None
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment

Verification:

Verified 01 Sept 2016 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria